New drug combo shows promise against rare thymus cancers

NCT ID NCT01025089

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 30, 2026 · Updated 2 times

Summary

This study tested whether adding the targeted drug cetuximab to standard chemotherapy could shrink advanced thymoma or thymic carcinoma tumors before surgery. 18 adults with stage II to IVA disease received the combination, then had surgery to remove any remaining tumor. Researchers measured how many patients had no cancer cells left in their surgical sample and tracked side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL MASAOKA STAGE II TO IVA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

thymic carcinoma thymoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL MASAOKA STAGE II TO IVA THYMIC CARCINOMA THYMOMA

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010-3000, United States
Md Anderson Cancer Center

Houston, Texas, 77030, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Cancer Center @ Suffolk

Commack, New York, 11725, United States
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center

Sleepy Hollow, New York, 10591, United States
Memorial Sloan Kettering West Harrison

Harrison, New York, 10604, United States
Memorial Sloan Kettering at Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering at Mercy Medical Center

Rockville Centre, New York, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.